
John Mitrofanis: Biophotons, Internal Melanins & Photobiomodulation
Ricci Flow Nutrition Podcast
Exploring Methylene Blue for Parkinson's and Unifying Similarities with Alzheimer's
Exploring the potential benefits of methylene blue and red light therapy in treating Parkinson's disease, discussing its mechanism as an electron donor and similarities with Alzheimer's disease in terms of neurodegeneration and protein accumulation.
John Mitrofanis, PhD, is a world leading researcher on the impact of photobiomodulation and neurodegenerative disease. His work has been centred around seeking effective drug-free treatments and preventative measures for Parkinson’s and Alzheimer’s disease. A former professor of anatomy at the University of Sydney, John is now based in France, where he works at the biomedical research centre, Clinatec in Grenoble France. John is beginning exciting work on biophoton release, examining how photobiomodulation might alter the release of these photons from neurones and other cell types. In his book, Run in the Light, John outlines the most current understanding of the pathologies involved in Parkinson's disease, and how both exercise and photobiomodulation can be used as inexpensive, simple and essentially no-risk modalities to both prevent and delay the progression of the disease. John is extremely humble and open-minded; excellent qualities to explore deep scientific questions.
Listen to our previous conversation
John's Work
- Why and how does light therapy offer neuroprotection in Parkinson's disease?
- Does photobiomodulation require glucose to work effectively?
My Work